Comparison of Efficacy of Two Dose Rates of Histrelin to Human Chorionic Gonadotropin for Inducing Ovulation in Broodmares

Abstract

Between February 15 and May 17, 2011, a total of 88 broodmares (10 maiden, 10 barren, and 68 foaling) maintained on pasture in southeast Texas were examined three times weekly (Tuesday, Thursday, Saturday) by transrectal palpation and ultrasonography. On Tuesday or Thursday, mares in estrus with uterine edema, a relaxed cervix, and a dominant follicle ≥34 mm in diameter were alternately assigned to treatment with the following: group (1) 2,500-unit human chorionic gonadotropin (hCG), intravenous; group (2) 1.0-mg BioRelease Histrelin (Biorelease Technologies, Lexington, KY), intramuscular; or group (3) 0.5-mg BioRelease Histrelin, intramuscular. Ovulation was confirmed by ultrasonographic examination. The percentage of mares ovulating within 2 days appeared to be similar between maiden, barren, and foaling mares, so responses for all mares were totaled for analysis. A nonsignificant trend for higher ovulation rates within 2 days was noted for both dose rates of histrelin compared with hCG treatment (31/37, 84%; 34/37, 92%; and 33/36, 92% for groups 1-3, respectively) (P = .45). Ovulatory responses appeared to improve for both products as the season progressed, yet no differences were detected between response rates to histrelin or hCG for any month (P ≥ .50). The use of 1.0- or 0.5-mg BioRelease Histrelin was found to be at least equally effective as hCG treatment for inducing ovulation within 2 days of treatment throughout the breeding season.